Curocell (372320.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
Curocell financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 KRW | – |
| Gross profit | 0.00 KRW | – |
| Operating income | -36.62 bn KRW | -36.29 bn KRW |
| EBIT | -35.63 bn KRW | -41.76 bn KRW |
| Net income | -38.24 bn KRW | -46.31 bn KRW |
| Diluted EPS – continuing operations | -2,693.04 KRW | -3,073.95 KRW |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Curocell
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.
More stocks
- Baoding Dongli Machinery Co.Ltd. (301298.SZ)
- Qingyan Environmental Technology Co. Ltd. (301288.SZ)
- Sichuan Langsha Holding Ltd (600137.SS)
- China Steel Structure Co Ltd (2013.TW)
- Dongsung FineTec Co. Ltd (033500.KQ)
- Hyundai Hcn (126560.KS)
- Lyons Bancorp Inc (LYBC)
- Polight ASA (PLT.OL)
- Cosmo Chem (005420.KS)
- Profit Cultural & Creative Group Co Ltd (300640.SZ)
- Nice Information & Telecommunication Inc (036800.KQ)
- Bookook Sec (001270.KS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.